Triple Oral Therapy Versus Antitumor Necrosis Factor Plus Methotrexate (MTX) in Patients with Rheumatoid Arthritis and Inadequate Response to MTX: A Systematic Literature Review

Julia Mary (1, 2, 3) , Michel de Bandt (1) , Cedric Lukas (2, 3) , Jacques Morel (2, 3) , Bernard Combe (2, 3)

1 Hôpital Pierre Zobda-Quitman [CHU de la Martinique]
2 Département de Rhumatologie[Montpellier]
3 IGMM - Institut de Génétique Moléculaire de Montpellier

For patients with rheumatoid arthritis (RA) who have an inadequate response to methotrexate (MTX), the relative effectiveness of the combination of conventional disease-modifying antirheumatic drugs (DMARD) compared with the combination of tumor necrosis factor (TNF) inhibitors and MTX, as second-line therapy, is uncertain. The aim of this study was to compare the efficacy and tolerance of triple oral DMARD therapy versus anti-TNF agents associated with MTX in patients with RA after MTX failure.

Mots clés: CONVENTIONAL TREATMENT; DMARD; RHEUMATOID ARTHRITIS; TNF INHIBITORS; TRIPLE THERAPY

Domaines: Rhumatologie et système ostéo-articulaire

Julia Mary, Michel de Bandt, Cedric Lukas, Jacques Morel, Bernard Combe. Triple Oral Therapy Versus Antitumor Necrosis Factor Plus Methotrexate (MTX) in Patients with Rheumatoid Arthritis and Inadequate Response to MTX: A Systematic Literature Review. Journal of Rheumatology, 2017, 44 (6), pp.773 - 779. ⟨10.3899/jrheum.160643⟩. ⟨hal-01762822⟩